• About
    Mission and HistoryExpertsIndependence and TransparencyInternships/Research Fellows
  • Explore Our WorkExplore Our Work
    • Our Work
      • Work
        • Amicus Briefs
        • Diversity and Inclusion
        • Economic & Policy Analysis
        • Fair Fight Film
        • Grant Research
        • Legal Analysis
        • Podcasts
        • Public Comments and Testimony
        • Reports
      • Issues By Sector
        • Airlines
        • Banking & Finance
        • Digital Technology
        • Energy
        • Food & Agriculture
        • Health & Pharmaceuticals
        • Innovation & Entrepreneurship
        • Intellectual Property
        • International
        • Labor
        • Media & Communications
        • Retail & Distribution
        • Transportation
      • Issues By Enforcement Area
        • Buyer Power
        • Cartels
        • Collusion
        • Exemptions & Immunities
        • Mergers
        • Monopolies
        • Private Enforcement
        • Public Enforcement
  • Events
  • Awards
    Alfred E. Kahn Award for Antitrust AchievementAntitrust Enforcement AwardsPrivate Antitrust Enforcement Hall of FameHollis Salzman Memorial Leadership AwardJerry S. Cohen Award for Antitrust Scholarship (administered by Cohen Milstein and hosted by AAI)
  • CLE Programs
  • Support
    Supporting AAIDonateSponsorshipsCy PresGrants
Amicus Briefs

Louisiana Wholesale Drug Co. v. Bayer AG (Cipro Reverse Payments)

January 21, 2011 Paul Slater
Health & Pharmaceuticals

AAI filed an amicus brief urging the Supreme Court to grant certiorari to reverse the Second Circuit’s rule of virtual per se legality for payments by branded drug manufacturers to delay entry by generics.  The brief was written by attorney Paul Slater.

AAI Amicus Brief

Related Work

Amicus Briefs

AAI Asks Third Circuit to Apply Practical Approach to Ascertainability Requirement for Class Cert.

May 31, 2023 | Joshua P. Davis
Health & Pharmaceuticals
Amicus Briefs

AAI Tells Second Circuit that Pharma Bro’s Lifetime Ban from the Pharmaceutical Industry is Appropriate and Necessary to Ensure Effective Relief

April 5, 2023
Health & Pharmaceuticals , FTC , Public Enforcement
Economic & Policy Analysis

CPI Antitrust Chronicle Features AAI Analysis on “Market Power Bottlenecks” in Supply Chains

July 5, 2022
Buyer Power , Mergers , Health & Pharmaceuticals , Food & Agriculture
Amicus Briefs

AAI Asks Second Circuit for Clear Thinking When Pharmaceutical Markets Are Monopolized by Patent Fraud (Regeneron v. Novartis)

June 20, 2022 | Randy Stutz
Exclusionary Conduct , Intellectual Property , Monopolies , Health & Pharmaceuticals

Support AAI

Promoting competition that protects consumers, businesses, and society is more important than ever. Through our research, education, and advocacy programs, AAI has been active in focusing public and private competition enforcement priorities and shaping progressive competition policy. The only way for AAI to fulfill its mission is through your support.

Learn More

Address

1025 Connecticut Avenue, NW
Suite 1000
Washington, DC 20036
(202) 828-1226

Join Our Mailing List

    • About
    • Terms of Use
    • Contact Us
    • Support

    Copyright © American Antitrust Institute 2023